Celltrion Signs ‘Incubation’ Agreement on New Drugs for Atherosclerosis
The Pharma Letter website reported that South Korean drugmaker Celltrion has signed an ‘incubation’ agreement with Emory University in Atlanta, to support the research and development of new drug candidates for atherosclerosis. An ‘incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or start-up so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output. A Celltrion official said, “Based on this incubation agreement, Celltrion will make further plans to secure more various new drugs and technologies. We are hoping that more research institutes and corporations will take an interest in our open innovation.”
Click here to read the full article.